Leica Microsystems, world-leading providers of Total Digital Pathology solutions, and Visiopharm the leading provider of Histoinformatics Solutions for Life-Sciences, today announce the completed integration of Leica’s SlidePath Digital Image Hub with Visiopharm’s Whole-Slide Informatics™ solutions for Digital Pathology.
Users can now take advantage of superior image capture and management from Leica Microsystems and excellent Whole Slide image analysis and Whole Slide Stereology from Visiopharm in a single system.
Author Archives: ev1
Innovative Industry Leaders to Share Advanced Digital Pathology Knowledge
A distinguished field of 41 speakers will highlight the hot topics in the world of digital pathology at the 2011 Pathology Visions Conference. Telemedicine, neuropathology, and the image analysis of biomarkers are just some of the subjects experts will discuss at the 7th annual Digital Pathology Association Conference Oct. 30 – Nov. 2 in San Diego, CA.
(PRWEB) August 17, 2011
What are the hot topics in digital pathology today? Telemedicine, neuropathology, image analysis of biomarkers: These are just some of the topics experts will discuss at the 2011 Pathology Visions Conference. Forty-one distinguished experts will share their in-depth knowledge in the clinical, education and research areas at the 7th annual Digital Pathology Association Conference Oct. 30 – Nov. 2 in San Diego, CA.
“Access to sub-specialist pathologists using telepathology and image analysis of biomarkers are two of the strongest value propositions for why institutions adopt digital pathology,” said Dirk Soenksen, President of the Digital Pathology Association and Chair of the Pathology Visions Program Committee. “Attendees at this year’s conference will learn best practices for these and other applications of digital pathology, as well as how digital pathology can improve patient care and enable personalized medicine.”
In the clinical arena, Clayton Wiley, M.D., Ph.D., will discuss inter-institutional and interstate tele-neuropathology. Dr. Wiley will share his knowledge on telemedicine and its emersion as an efficient means of distributing professional medical expertise to geographically dispersed sites. He’ll also share his expertise on neuropathology and why it’s well-suited to utilize telepathology.
Tony Magliocco, M.D., will highlight the development of quantitative microscopy methods as prognostic and predictive cancer biomarkers. The digital pathology research expert will discuss three emerging analytical methods that hold promise for routine diagnostic pathology, including fractal analysis, analysis of DAB stained ki67 tissues with a focus on breast cancer, and the use of multiplex fluorescent imaging to study "functional tissue dynamics."
Early pathologists started laying the groundwork for the digital pathology industry nearly a century and a half ago.Dr. Clive Taylor, M.D.,D. Phil., will give the audience a history lesson about the journey from microscopy to whole slide images. Dr. Taylor’s insight into how the past has shaped our industry will give attendees a firmer grasp on the important role they will play in the future of digital pathology.
These three speakers offer just a sneak peek at a line-up filled with distinguished presenters. The Pathology Visions Conference will host 38 additional research, education and clinical experts. Click here for a complete list of the speakers and details of their presentations.
Conference attendees will also have the opportunity to earn up to 13 CME credits, take part in an FDA panel discussion, and participate in cutting-edge industry workshops. DPA white paper and scientific poster sessions, roundtable discussions, networking events, and dozens of exhibitor displays will round out the three day conference. Register now for the internationally-acclaimed conference.
The Pathology Visions Conference is also offering a special discounted rate for conference guests. For a reduced registration fee, your spouse or special guest can attend all meals and the Sunday evening welcome reception.
The mission of the Digital Pathology Association is to facilitate education and awareness of digital pathology applications in health care. Members will be encouraged to share best practices and promote the use of the technology among colleagues in order to demonstrate efficiencies, awareness, and its ultimate benefits to patient care.
DigiPath Licenses Olympus Digital Pathology Patents
DigiPath follows course of several whole slide imaging device manufacturers and licenses Olympus patents.
HENDERSON, Nev. and CENTER VALLEY, Pa., USA, August 17, 2011 -- DigiPath, Inc®, a provider of affordable, innovative and reliable digital pathology solutions, and Olympus America Inc., a precision technology leader designing and delivering innovative solutions in life science imaging and other product areas, have entered into a nonexclusive worldwide agreement allowing DigiPath and its OEM partners to access an extensive portfolio of Olympus patents in the field of virtual microscopy and digital pathology. The patents involved in the licensing agreement cover methods, software and technology for creating, storing and delivering virtual microscopy images.
Virtual microscope slides enable professionals to review biopsies and other pathology images without handling traditional glass slides, and allow doctors to share high-resolution digital microscope images over telecommunication networks for second opinion consultation, tumor board review, and image archiving functions.
"Licensing these patented technologies and approaches to innovative new companies like DigiPath is very important to us," said Mr. Hidenao Tsuchiya, Vice President and General Manager of Olympus America Inc., Scientific Equipment Group. "Agreements like this help foster widespread digital imaging adoption where affordability and improving advanced patient care are vital."
"DigiPath is delighted to work with Olympus," said Eric Stoppenhagen, Chief Executive Officer for DigiPath. "Our clients and OEM partners can be assured their investments in digital pathology are stable and secure."
About DigiPath, Inc. DigiPath, Inc. provides the next generation of affordable, innovative, and reliable digital pathology solutions. DigiPath's advisors bring over 60 years combined expertise in pioneering digital pathology, implementing over 500 installations at community pathology practices, hospitals, academic medical centers, reference laboratories, biopharma organizations, and life science research institutions worldwide.
About Olympus Scientific Equipment Group Olympus America Scientific Equipment Group provides innovative microscope imaging solutions for researchers, doctors, clinicians and educators. Olympus microscope systems offer unsurpassed optics, superior construction and system versatility to meet the ever-changing needs of microscopists, paving the way for future advances in life science. Visit http://www.olympusamerica.com/microscopes.
About Olympus Olympus is a precision technology leader, designing and delivering innovative solutions in its core business areas: Medical and Surgical Products, Life Science Imaging Systems, Industrial Measurement and Imaging Instruments and Cameras and Audio Products. Olympus works collaboratively with its customers and affiliates worldwide to leverage R&D investment in precision technology and manufacturing processes across diverse business lines.
These include:
Olympus serves the healthcare field with integrated product solutions and financial, educational and consulting services that help customers to efficiently, reliably and more easily achieve exceptional results. Olympus develops breakthrough technologies with revolutionary product design and functionality for the consumer and professional photography markets, and also is the leader in gastrointestinal endoscopy and clinical and educational microscopes. For more information, visit http://www.olympusamerica.com.
Olympus is a registered trademark of Olympus Corporation, Olympus America Inc., and/or their affiliates in the U.S. and/or other countries. |
2nd International Definiens Symposium 2011
PROGRAM SPEAKERS - Top Notch Line Up!
After the great success and feedback from the Definiens Symposium 2010 in Madrid, Definiens is pleased to announce the International Definiens Symposium 2011. The venue will take place at the Moffitt Cancer Center in Tampa, Florida, October 17-18, 2011. We invite you to join this event to hear about groundbreaking research, meet other users and share your ideas.
The annual Definiens Symposium is the premier forum for Definiens users and developers from around the world to present their latest research, techniques and workflows in life science image and data analysis. Participants come from research institutions, bio-pharmaceutical companies and the healthcare sector.
Venue: H. Lee Moffitt Cancer Center and Research Institute, Vincent A. Stabile Research Building, 12902 Magnolia Drive, Tampa, FL 33612, USA
The 2011 Definiens Symposium will be an ideal opportunity to share the latest ideas in state-of-the-art image analysis and to meet international experts from the Definiens community.
Sessions will include:
- Biomarker Development and Validation
- Basic Research and Drug Discovery
- Toxicity and Efficacy Studies
- Clinical Diagnostics
A social networking event will take place in Tampa's latin quarter, Ybor City, on Monday evening. Transportation between the Symposium venue and the evening event will be arranged.
2011 CAP Election Results
Congratulations to Dr. Gene Herbek and the newly elected governors. Excellent choices!
From CAP: The results of this summer’s ballot for the CAP election are now final. The College would like to thank all Fellows and Life Fellows who voted in this year’s election.
The winners of this year’s election are:
- President-elect:
- Gene N. Herbek, MD, FCAP, Omaha, Nebraska
- Governors:
- Patrick E. T. Godbey, MD, FCAP, Brunswick, Georgia
- William F. Hickey, MD, FCAP, Lebanon, New Hampshire
- Stephen J. Sarewitz, MD, FCAP, Renton, Washington
- Elizabeth A. Wagar, MD, FCAP, Houston, TX
The results will be officially announced and the winners sworn in at the CAP Business Meeting in conjunction with the House of Delegates/Residents Forum joint session on Saturday, September 10, 2011, in Grapevine, Texas. All CAP members are welcome to attend.
Pathology woes continue in Canada
From Dark Daily 8/15/2011: Even as the Province of Manitoba deals with some highly-publicized issues in anatomic pathology, over in the neighboring Province of Saskatchewan, a sizeable backlog in anatomic pathology cases earlier in the year caused the Saskatoon Health Region to refer pathology cases to another region within the province.
Read full story at Dark Daily.
Do you order stains requested by clinicians?
Dr. Tom Wheeler has an interesting blog post over at his blog Lab Line by the Doctor’s Doctor.
It starts "I was out of town attending a conference when I got an email from an infectious disease internist wondering if I had done the AFB stain on a bone biopsy that had been specifically ordered by the attending physician on the pathology requisition slip accompanying the specimen. On the surface this might seem as a reasonable request – the patient had been treated for active tuberculosis involving the bone for over one year and there was a desire to complete the placement of an artificial joint, but only if the tissue was negative for TB."
One of many comments received mentioned "You forget your place; yours is to perform a test at the direction of the attending physician (and in most cases that test is set up by a technician for you to review so you aren't in on the front end). You are not the physician of record and while you have an opinion and level of knowledge that the ordering physician may not (or then again they may have) you do not get to dictate to the "Customer of the Lab" whether or not you will perform the service ordered. Try that on a regular basis and they will take their business elsewhere and there are literally hundreds of labs looking for work. "
Dr. Wheeler goes on to explain that in communication with the clinician, justification for not ordering the stain was provided with an amicable resolution of the matter and reassurance to the clinician was provided and all ended well. The stain was not done; Dr. Wheeler exercised his right as a physician to use his judgement based on what he knew and saw of the case and did not perform the test, even though it was specifically requested by the ordering physician.
The anonymous comment above takes a different approach and one I must admit is more like I have thought and generally follow. If a specific stain is ordered, take congo red, to rule out amyloid, I could either a) after reviewing the case if I think it is warranted, order the stain; b) order the stain even if I do not think the histologic findings warrant doing so but performing the stain "just in case"; c) order the stain regardless of what I see on the histology to avoid a subsequent phone call, e-mail or text asking me why I did not order the stain; d) not perform the stain based on what I see on the histology and head off the question or another request to do so with my own phone call or e-mail.
Depending on the particular request, I must admit I sometimes take the easy way out and do the stain becuase I think if the clinician made the request, they may have some information I do not have in front of me or in the EMR (yes, this does happen -- EMRs only contain information someone puts into them), unless I think the request if completely off the wall. This way when they ask about the stain, I can report it was done at their request and was negative.
To some extent, we do this already as standing orders, which in some cases, are not justified. Helicobacter stains on all "gastric" biopsies. Alcian blue stains on all "esophagus" or liver "panels". The problem is that for non-gastritis, non-Barrett's cases and liver biopsies to rule out tumors, you may still get stains that are not warranted. Why is this done? Because the clinicians usually requested it at some point -- Dear medical diretor/chairman/group head -- please do a Helicobacter stain on all stomach biopsies or an alcian blue on all esophagus biopsies so "you don't miss anything".
What do you do/does your practice do about specific stain requests? Which ones do you do routinely largely because, historically, a clinician or group of clinicians made a standing request at some time?
Seoul, Korea








Hi all. My sincere apologies for falling behind on Morbid Anatomy. I am currently living in Seoul, Korea as part of the very generous Apex Art Outbound Residency Program (thanks, Josh Foer!), and one of the obligations of the residency is to blog about my experiences. Sadly, this had taken my focus off Morbid Anatomy a bit.
I promise to do my best over this next month in Korea to get some Morbid Anatomy reportage done; in the meantime, if you are curious about what I am finding in Seoul, you can check out my Apex Art blog here.
Thanks for your patience, and I will be back in full force in mid-September!
Source:
http://morbidanatomy.blogspot.com/feeds/posts/default?alt=rss
Low-carb diet may reverse kidney failure in diabetics, says new research
A new study shows that a low carbohydrate, high fat diet, used typically to treat and control seizures in children with epilepsy, may reverse kidney failure in people with diabetes.
Researchers from Mount Sinai School of Medicine have found that the ketogenic (low carbs, high fat) diet is useful as many cells can get energy from ketones.
Ketones are molecules produced when the blood glucose levels are low and blood fat levels are high. It has been shown that when cells use ketones instead of glucose for energy, glucose is not metabolized. As high glucose metabolism is what causes kidney failure in diabetics, the Mount Sinai researchers theorized that introducing a ketogenic diet would work to block the toxic and very harmful effects of the glucose. Read more...
Source:
http://anti-aging-for-today.blogspot.com/feeds/posts/default?alt=rss
Interview With Dr. Bruce Ames – An Anti Aging Specialist
Life Extension Magazine recently did an interview with Dr.Bruce Ames, an anti aging specialist and research scientist who was the first to realize the potential of using lipoic acid and Acetly L Carnitine together to help reverse the aging process.
You may remember I originally wrote about this combination in this article: Anti Aging for the Brain and Body .
Dr. Ames has recently developed the Triage Theory of Aging, which found that moderate deficiencies of one of the 40 essential nutrients may lead to DNA damage - which in turn, leads to disease and aging.
Interview With Dr. Bruce Ames – An Anti Aging Specialist is a post from: Anti Aging Nutrition News
DICOM Standard 2011 Edition now available
Blood Test For Baby’s Gender Accurate, Potentially Controversial
On its front page, the New York Times (8/10, A1, Belluck, Subscription Publication) reports that according to a study published in the Journal of the American Medical Association, "a simple blood test that can determine a baby's sex as early as seven weeks into pregnancy is highly accurate if used correctly." Experts predict that "parents concerned about gender-linked diseases, those who are merely curious, and people considering the more ethically controversial step of selecting the sex of their children" are all likely to utilize this technology. The Times says similar tests have previously been commercially available but were often inaccurate. In response to concerns of gender selection, some companies require waivers from customers saying they will not use the test for that purpose.
USA Today (8/10, Szabo) reports, "The technology works by detecting 'cell-free fetal DNA,' or DNA from the fetus, which floats freely in a pregnant woman's blood." USA Today also notes specific concerns about possible misuse of the technology, citing a study in The Lancet estimating that "between 4.2 million and 12.1 million female fetuses were 'selectively' aborted in India from 1980 to 2010, a practice that is noticeably skewing the ratio of boys and girls in that country."
The AP (8/10, Tanner) specifies that the procedure tested in this study uses a PCR test for Y chromosome DNA to tell whether the fetus is biologically male or female. AP notes that testing was performed in research settings, while "tests that companies sell directly to consumers were not examined in the analysis." Researchers stated that "blood tests like those studied could be a breakthrough for women at risk of having babies with certain diseases, who could avoid invasive procedures if they learned their fetus was a gender not affected by those illnesses."
The Los Angeles Times (8/9, Khan) "Booster Shots" blog reported, "The researchers found that tests...are about 95% to 99% accurate, depending on several factors. They can be used well before ultrasound...and aren't invasive, unlike amniocentesis, which carries a small but real risk of miscarriage." However, science writer Karen Kaplan warns that "There's a whole industry of questionable genetic tests put out by 'entrepreneurs' that promise to tell parents-to-be practically anything about their future children, from ethnic heritage to most viable future sports activities."
The Wall Street Journal (8/9, Hobson, Subscription Publication) "Health Blog" noted that some diseases, such as congenital adrenal hyperplasia, require corticosteroid treatment of the mother throughout her pregnancy if the fetus is female. Therefore, the test would find that a woman carrying a female child with this condition should be treated, while a woman carrying a male child with the condition could avoid such treatment.
According to the Boston Globe (8/9, Kotz) "Daily Dose" blog, currently available tests in the US are unregulated by the US Food and Drug Administration. Notably, "Several years ago, Lowell-based Acu-Gen Laboratories promised that its Baby Gender Mentor blood test was '99.9 percent accurate' in detecting a fetus's sex at five weeks and offered refunds to anyone who received wrong results. The company was forced into bankruptcy in 2009 after hundreds of women with false results filed class action lawsuits after they said they weren't given any refunds." The researchers who published this study said the Acu-Gen test detected the "Y chromosome only 41 percent of the time."
In a commentary for MSNBC (8/9), University of Pennsylvania Center for Bioethics director Arthur Caplan wrote that outside of testing for sex-linked genetic diseases, "everything about the early testing of fetal genes for sex identification spells ethical trouble." Caplan predicted these tests will soon be used for gender-selective abortion, paternity testing, and whether "your 7-week-old fetus is prone to early onset breast, colon or ovarian cancer, Down syndrome, cystic fibrosis, sickle cell disease, dwarfism, deafness, Alzheimer's." Caplan argued this test "promises to soon be a very morally contentious technology."
MedPage Today (8/9, Fiore) reported, "In a review and meta-analysis, detection of Y-chromosome sequences had a sensitivity of about 95% and a specificity of nearly 99%, Stephanie Devaney, PhD, of the National Institutes of Health in Bethesda, Md., and colleagues reported." Researchers stated "that a disadvantage of fetal DNA blood testing is the need to validate female sex, because the test looks for male, or Y-chromosome, DNA." MedPage Today also noted that the National Human Genome Research Institute funded the study.
Killer App Discovered for Digital Pathology
10 August 2011 -- Fenway, MA. After many years of anticipation, a killer application has finally been discovered for digital pathology, by researchers at the Fenway University in Boston, Massachussetts. "One would think that simply being able to work from anywhere, share anything, with a full audit trail of what was viewed, and the ability for the computer to assist in scoring would be enough to drive digital pathology adoption," said Dr. Mark Lowell, Professor at Fenway University. "However, the industry has been waiting for a killer application to drive adoption, and we believe we have finally found it."
"We studied pathologist patterns while at the microscope and while traveling to peer reviews, conferences, and tumor boards, and we were struck by an amazing pattern. Pathologists that regularly flew through Newark Airport, were far more likely to go digital in their work than those that did not fly through this airport. Basically, we modified an advanced pattern recognition software that was previously only used in over-training results in gene expression datasets, and applied this to pathologist commuting patterns. The trend was consistent everywhere in the United States, the more a pathologist has to travel through Newark Airport, the more likely he or she will stay home and read slides digitally."
"These results fit well with other evidence we examined in our algorithm," said Dr. Karlton Phisk, a co-author in the study. "First, a ranking of airports has Newark rated first for the most delays. Second, we noticed that pharmaceutical pathologists seem to be adopting digital slides faster than clinical anatomic pathologists, and we can attribute this directly to them having to fly more frequently through Newark for corporate pharma meetings. Third, the Cambridge area of Boston is adopting digital pathology faster than other parts of the United States. Clearly Boston pathologists hate having to travel through the New York area more than other pathologists would, given the historic rivalry between these two cities."
"Saving even one trip through Newark is well worth the purchase of multiple scanners," said Dr. Karl Yastemsky, a third author on the study. "Actually, avoiding New York City for any reason is worth spending a few additional seconds to view the images digitally versus with glass."
The results are not without controversy, on both sides of the Atlantic. In the United States, Professor R. Ruffen of Yanqui University in New York City strongly disagreed with the study's conclusions. "First, scientists in Cambridge will buy anything, and second, Newark is a beautiful airport. You can see all of New York City multiple times while circling the airport on most flights. If we applied the logic used in this study, we would expect to see British pathologists also adopting whole slide imaging faster than their peers, because Heathrow Airport is one of the worst to fly through."
The study's original authors disagreed with Dr. Ruffen's logic challenge comparing Heathrow to Newark. "Everyone knows that British pathologists will take every chance they can get to travel, in hopes of escaping bad food and bad weather, so the effect of Heathrow is a net neutral effect," said Mr. Jon Riddeck, a up and coming star and graduate student at Fenway University, and the fourth author on the study. "Although to be fair, the British breakfasts are quite good, but probably not enough to keep pathologists from traveling abroad" he added.
At a recent pathology meeting, several English pathologists first apologized for their Heathrow Airport as well as their weather and their food, but then asked why they were included in this controversy, that seemed entirely American in nature and had nothing to do with them.
Submitted anonymously to avoid reprisals from anyone and everyone
Animal shapes in pathology
China Medical Technologies and Leica Microsystems Announce Collaboration
Last month it was announced that Mayo Medical Laboratories entered into a pathology testing agreement with a Chinese medical laboratory. Earlier this year both UCLA and UPMC announced telepathology initiatives with China. Now comes word that Leica has entered into collaborative efforts for joint sales, research and development with a Chinese company:
Beijing, China / Wetzlar, Germany. China Medical Technologies, Inc. (CMED) (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic (“IVD”) company, and Leica Biosystems, a division of Leica Microsystems, a world leader in microscopes and scientific instruments, today announced that they have established a sales, research and development collaboration to co-develop and market automated FISH kits to be used on the Leica BOND system. CMED will sell the Automated FISH Kits in China and Leica will have an option to sell the FISH kits in the rest of the world.
Under the collaboration, CMED and Leica Microsystems will jointly develop automated FISH solutions for tissue sample tests on HER-2, EGFR and TOP2A on the Leica BOND system, an automated advanced staining platform. HER-2, EGFR and TOP2A are genes in connection with the targeted cancer therapy drugs for breast cancer, lung cancer and stomach cancer patients. Automation of these FISH tests on the Leica BOND system will enable pathology laboratories and independent service laboratories to run these diagnostic tests more efficiently and with higher and more consistent quality. The automation of FISH tests will also help users to reduce the work load pressure created by increasing test volumes. Both parties agreed to add further FISH applications into the collaboration during the term, including for cytology and pre-natal applications.
“These collaborations with Leica mark a significant milestone for us,” commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of CMED. “We believe that FISH applications will be more widely used in various clinical applications on automated basis in the future. By partnering with Leica, one of the leading global players anatomic pathology, we can provide more efficient and higher quality FISH diagnostic solutions to the end users not only in China, but also in the global markets through Leica’s extensive global network.”
“CMED is the market leader for FISH based diagnostics in China and has played a key role in the rapid development in the use of FISH in China, especially for tissue based companion diagnostic testing. This partnership will help Leica and CMED to offer customers in China a broad test menu of high quality FISH tests automated on the Leica BOND system,” commented Arnd Kaldowski, President of Leica Biosystems.
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Leica Microsystems is a world leader in microscopes and scientific instruments. Founded as a family business in the nineteenth century, the company’s history was marked by unparalleled innovation on its way to becoming a global enterprise. Its historically close cooperation with the scientific community is the key to Leica Microsystems’ tradition of innovation, which draws on users’ ideas and creates solutions tailored to their requirements. At the global level, Leica Microsystems is organized in four divisions, all of which are among the leaders in their respective fields: the Life Science Division, Industry Division, Biosystems Division and Medical Division.
Leica Microsystems’ Biosystems Division, also known as Leica Biosystems, offers histopathology laboratories the most extensive product range with appropriate products for each work step in histology and for a high level of productivity in the working processes of the entire laboratory.
The company is represented in over 100 countries with 12 manufacturing facilities in 7 countries, sales and service organizations in 19 countries and an international network of dealers. The company is headquartered in Wetzlar, Germany.
China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com.
Olympus VS120 Announcement
The VS120 virtual microscopy slide scanning system from Olympus scans faster than ever before, offers image deconvolution/deblurring for ultra-sharp images and provides important fluorescence imaging capabilities. Virtual slide creation could not be simpler—just set the slide in place and press Start. The system creates outstanding brightfield slide scans up to three times faster than was possible with earlier systems, making it ideal for training, education, archiving and research.
The VS120 is the latest in a series of Olympus virtual microscopy systems that can scan up to 100 slides at a time at very high fidelity, so that users anywhere in the world can view and fully navigate high-resolution images of entire microscope slides or slide areas using a computer. It comes equipped with a 5-megapixel CCD brightfield camera that improves brightfield scanning speeds while delivering superb color reproduction and ultra-high resolution.
Olympus is a world leader in fluorescence microscopy, and no other virtual microscopy system available today can match the fluorescence slide scanning performance of the VS120.
Acquiring sharp images at multiple depths using six or more fluorescence labels is possible, thanks to OlympusFluorescence Virtual-Z capability. The software adjusts for the potentially different focal positions of various wavelengths in multichannel acquisition. Automated batch scanning can be accommodated with fluorescence samples and individual shading correction isavailable for each color channel. In addition, the VS120 provides for online deblurring during fluorescence acquisition, which vastly improves image sharpness in real time.
“The VS120 provides users with the exceptional optical performance and reliability people have come to expect from Olympus, which is renowned for both research microscopy and pathology imaging,” said Brad Burklow, director of business development for the Olympus America Scientific Equipment Group.
In addition to its faster scan speeds, the system offers more than 30 software enhancements. No-neighbor and nearest-neighbor deconvolution are available offline and a wide range of measurement and annotation functions are supported. Images can now be saved in .tiff and .btf file formats, along with the .vsi virtual slide file format. To support users working simultaneously with images from the Nanozoomer virtual microscopy scanning system, the .ndpi file format is supported.
The VS120 is built around the Olympus renowned optical and microscope technologies. For superior optical performance and scanning flexibility, Olympus Plan Apo 2x, 10x, 20x and 40x objectives come as standard, with optional 60x and 100x Plan Apo oil objectives for high-magnification oil immersion scanning.
Source: Olympus America Inc.
Read more at Olympus Virtual Microscopy site.
Corpus Illuminata: An Anatomic Interpretation, Detroit, August 12th and 13th

Just got word of an interesting looking event/exhibition taking place this weekend in the ever fascinating Detroit. Full details follow:
In the Evening of the 12th and 13th Day of August 2011, it will be unveiled an extraordinary exposition of biological and medical exploration entitled Corpus Illuminata - An Anatomic Interpretation. Hosted within the District VII Gallery in Detroit, this unique event will consist of one part exhibition of anatomic-inspired artwork, one part museum of medical antiquities and one part academia of accredited presentations.
The exhibition portion will feature 33 artistic explorations from 24 artists local and across the nation. Within the museum portion, collectors of Victorian-era medical instruments, quackery and oddities will bring together their cherished pieces to re-create themed display rooms ranging from surgical to mortuary. On stage, various speakers will present and discuss a variety of topics that include human anatomy, psychology, the history of contraception, the chemistry of herbal supplements and other intriguing subject matters.
Video installations within the venue will be feature films and videos ranging from historical medical experimentations, human autopsies, artistic interpretations and more. The ambiance is supplied by Life Toward Twilight from the new CD "I Swear By All The Flowers", which explores memories from the end of the Nineteenth Century through a sound collage from antique sources, including music boxes, ticking grandfather clocks, steam trains, wax cylinder recordings, early mechanical factories and old voices. Also, gelatos, gelato floats and flavored teas, courtesy of the Detroit Tea Company, will be served within our apothecary-themed health bar.
The doors open at 6pm on both evenings until midnight and all ages are welcome, however discretion must be advised due to some graphic medical content.
Admission is only five dollars.
You can find out more about this event here.
Teaser for The Midnight Archive, a New Web Video Series Based Around the Event/Gallery Space Observatory, Brooklyn
Film maker, friend, and many-time Observatory lecturer Ronni Thomas finds Observatory--the event and gallery space I founded with some friends in Brooklyn New York a few years back--inspiring. So inspiring, in fact, that he has created a new web-based video series entitled "The Midnight Archive: Tales from the Observatory" which will use as a launching off point the events, classes, field trips and personalities to be found in this space.
This Friday night we will be hosting a launch party for The Midnight Archive at The Coney Island Museum as part of my ongoing exhibition The Great Coney Island Spectacularium; more on that party can be found here.
In the meantime, above is a teaser for the show, which features five Observatory presenters--including our self-taught anthropomorphic taxidermy and mummification instructors--and is graced by the music of Stephen Coates of The Real Tuesday Weld. And following is what auteur Ronni Thomas has to say about this new series and its inspiration:
About an ODD year ago, or so, i had the honor to lecture at the ever impressive Brooklyn Observatory in, well... Brooklyn, NY. I was amazed at the turnout - I could not believe so many people were interested in such strange topics. Talking to Joanna Ebenstein of Morbid Anatomy and the Observatory itself, it seemed apparent that there was a demand for a series on the exotic and the esoteric.
Hence - The Midnight Archive... Its not only a web series but a collection - so to speak - of some of the unique people, collections, careers and artifacts from the Observatory as well as around the world. Consider it a sampler, an Observatory Sampler - like those Whitman's Chocolate Samplers (only don't crush each of these to figure out whats inside). The Series launches Friday August 12th at Coney Island USA - for details please email ronni [at] themidnightarchive.com
Title Theme by the ever amazing Stephen Coates (The Real Tuesday Weld, Lazarus and the Plane Crash) http://www.tuesdayweld.com.
Stay tuned for full episodes at themidnightarchive.com. For more on Friday's launch party--where at least one entire episode will be screened--click here. For more on Observatory--the space that inspired it all!--click here.
Olive oil provides amazing liver protection
You may want to drizzle a little extra olive oil on your next salad, according to findings from a new study out of the University of Monastir in Tunisia and King Saud University in Saudi Arabia. Researchers there found that extra virgin olive oil provides powerful antioxidant protection against toxins that cause oxidative stress and damage to the liver.
"Olive oil is an integral ingredient in the Mediterranean diet," explained Mohamed Hammami, author of the study. "There is growing evidence that it may have great health benefits including the reduction in coronary heart disease risk, the prevention of some cancers, and the modification of immune and inflammatory responses."
Hammami and his team tested the effects of olive oil on a group of rats exposed to a toxic herbicide called '2,4-Dichlorophenoxyacetic acid' that causes severe liver damage. Compared to control group rats who received no olive oil, the rats that consumed extra virgin olive oil in the presence of the herbicide experienced significantly increased antioxidant enzyme activity and a decrease in the biomarkers of liver damage. Read more...
Autopsy rates declining
There are a number of reasons for this, namely, ubiqutous pre-mortem imaging with improved techniques and detection of disease pre-mortem, lack of payment/reimbursement, more out of hosptial deaths and decreased number of physicians trying to obtain consent. I have seen the autopsy rate at some hospitals in my career as low as 8%. What is not clear to me is why/how JCAHO does not cite for these kinds of findings and why more is not done in clinical medicine to obtain consent for what is still widely considered the "gold standard" in medicine for clinicopathologic correlation and assessing effects of therapy and natural history of disease.
It is said the Virchow himself performed over 50,000 autopsies. I can't imagine doing that many, but these numbers are paltry.
The Wall Street Journal (8/4, Hobson) "Health Blog" reported that CDC statistics show that in 2007, autopsies were performed on 8.5% of deaths, compared with 19.3% of deaths in 1972. CDC scientist Donna Hoyert says this may be due to medical professionals believing that autopsies are unnecessary due to modern technology. However, doctors point out that autopsies can contradict imaging findings, and alert families to genetic conditions. The report also notes that the Joint Commission has removed a rule that hospitals must perform autopsies on 20% to 25% of deaths.
HealthDay (8/4, Preidt) reported that "in 1972, deaths due to disease accounted for 79 percent of autopsies, while deaths due to external causes such as injury or murder accounted for 19 percent. By 2007, the respective percentages were 46 percent and 50 percent, the investigators found. External causes of death -- including murder, accidental injury, suicide or undetermined cause -- accounted for nine of the 10 most frequently autopsied causes of death in 2007." The report also showed that "while the number of deaths among older people increased from 1972 to 2007, autopsied deaths were increasingly concentrated in the one to 34 and 35 to 64 age groups." WebMD (8/4, Hendrick) also covered the study.
http://blogs.wsj.com/health/2011/08/04/the-incredible-shrinking-autopsy/?mod=WSJBlog&mod=WSJ_health